JP5868869B2 - 光力学的療法のための乳酸・グリコール酸共重合体をベースにしたナノ粒子キャリアシステム - Google Patents
光力学的療法のための乳酸・グリコール酸共重合体をベースにしたナノ粒子キャリアシステム Download PDFInfo
- Publication number
- JP5868869B2 JP5868869B2 JP2012543222A JP2012543222A JP5868869B2 JP 5868869 B2 JP5868869 B2 JP 5868869B2 JP 2012543222 A JP2012543222 A JP 2012543222A JP 2012543222 A JP2012543222 A JP 2012543222A JP 5868869 B2 JP5868869 B2 JP 5868869B2
- Authority
- JP
- Japan
- Prior art keywords
- photosensitizer
- photodynamic therapy
- nanoparticles
- plga
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002105 nanoparticle Substances 0.000 title claims description 143
- 238000002428 photodynamic therapy Methods 0.000 title claims description 32
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims description 14
- 229920001577 copolymer Polymers 0.000 title claims description 8
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 title claims description 7
- 235000014655 lactic acid Nutrition 0.000 title claims description 7
- 239000004310 lactic acid Substances 0.000 title claims description 7
- 239000003504 photosensitizing agent Substances 0.000 claims description 99
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 78
- 239000002245 particle Substances 0.000 claims description 34
- 229940079593 drug Drugs 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 27
- 238000009472 formulation Methods 0.000 claims description 25
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 claims description 19
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- HORNXRXVQWOLPJ-UHFFFAOYSA-N 3-chlorophenol Chemical compound OC1=CC=CC(Cl)=C1 HORNXRXVQWOLPJ-UHFFFAOYSA-N 0.000 claims description 8
- 230000002209 hydrophobic effect Effects 0.000 claims description 8
- 150000004032 porphyrins Chemical class 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 150000004036 bacteriochlorins Chemical class 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical group N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- 208000012931 Urologic disease Diseases 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 229960002197 temoporfin Drugs 0.000 claims description 3
- 208000014001 urinary system disease Diseases 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000007908 nanoemulsion Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 239000002577 cryoprotective agent Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 230000000274 adsorptive effect Effects 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 27
- 239000011159 matrix material Substances 0.000 description 16
- 239000004372 Polyvinyl alcohol Substances 0.000 description 12
- 238000004108 freeze drying Methods 0.000 description 11
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 10
- BHPNXACHQYJJJS-UHFFFAOYSA-N bacteriochlorin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)CC2)=CC=C1C=C1CCC4=N1 BHPNXACHQYJJJS-UHFFFAOYSA-N 0.000 description 10
- ZUELZXZJXUXJCH-UHFFFAOYSA-N 3-[10,15,20-tris(3-hydroxyphenyl)-21,23-dihydroporphyrin-5-yl]phenol Chemical group Oc1cccc(c1)-c1c2ccc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 ZUELZXZJXUXJCH-UHFFFAOYSA-N 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 206010034972 Photosensitivity reaction Diseases 0.000 description 8
- 230000004700 cellular uptake Effects 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 238000009826 distribution Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 208000007578 phototoxic dermatitis Diseases 0.000 description 7
- 231100000018 phototoxicity Toxicity 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 239000000975 dye Substances 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical group C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 4
- 230000021164 cell adhesion Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 150000004033 porphyrin derivatives Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000006257 total synthesis reaction Methods 0.000 description 3
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- -1 photocrystals Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 241000122205 Chamaeleonidae Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 102000056372 ErbB-3 Receptor Human genes 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 101150050192 PIGM gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- KSXLETNRCMCRAQ-UHFFFAOYSA-N chembl383675 Chemical compound OC1=CC=CC(C=2C=3C=CC(N=3)=C(C=3C=C(O)C=CC=3)C3=CC=C(N3)C(C=3C=C(O)C=CC=3)=C3C=CC(N3)=C(C=3C=C(O)C=CC=3)C=3CCC=2N=3)=C1 KSXLETNRCMCRAQ-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229940125380 highly variable drug Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000005486 microgravity Effects 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Nanotechnology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
ポリマー
本発明で用いられるポリマーの限定しない例は、乳酸・グリコール酸共重合体PLGAであって、好ましくは50:50または75:25の共重合体比であることを特徴とする。本発明の基本的な調製に用いられるPLGAは、Boehringer Ingelheim社から取得された(Resomer RG502HおよびResomer RG504H)。
本発明で用いられる光増感剤は、好ましくは、これらに限定されないがクロリンおよびバクテリオクロリン類のテトラピロールである。当該光増感剤は、天然物由来でも全合成によるものであってもよい。クロリンおよびバクテリオクロリンの全合成は、はじめにポルフィリンの合成、続いてそれをクロリンおよびバクテリオクロリン系に変換することによって行われる(例えば、R. Bonnet-t, R. D. White, U.-J. Winfield, M. C. Berenbaum, Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumor photosensitizers, Bioehem. J. 1989, 261,277-280)。
光増感剤5,10,15,20‐テトラキス(3‐ヒドロキシフェニル)‐ポルフィリン(mTHPP)を含有するPLGA系ナノ粒子の調製と特徴付け;粒子マトリックスへの吸着および封入結合の組み合わせ
凍結乾燥工程において、トレハロースが3%(m/V)の濃度でナノ粒子試料に添加された。試料は、凍結乾燥機に移され、装置内温度が1℃/分の速度で5℃から−40℃に下げられた。圧力は、0.08mbarに設定された。これらのパラメータは、6時間維持された。0.5℃/分で−40℃から−25℃まで温度が上昇することによって、一次乾燥が終了した。圧力は変化させずに維持された。一次乾燥の熱傾斜の終了時点で、圧力上昇試験(PRT)が実行された。一次乾燥の終了に続いて、0.2℃/分で25℃まで温度を上昇させることで二次乾燥が行われた。この温度は、圧力60mT(=0.08mbar)で6時間維持された。
光増感剤5,10,15,20‐テトラキス(3‐ヒドロキシフェニル)‐クロリン、mTHPCを含有するPLGA系ナノ粒子の調製と特徴付け;粒子マトリックスへの吸着および封入結合の組み合わせ
光増感剤5,10,15,20‐テトラキス(3‐ヒドロキシフェニル)‐ポルフィリン(mTHPP)を含有するPLGA系ナノ粒子の調製と特徴付け;粒子マトリックスへの吸着のみによる結合
光増感剤5,10,15,20‐テトラキス(3‐ヒドロキシフェニル)‐クロリン、mTHPCを含有するPLGA系ナノ粒子の調製と特徴付け;粒子マトリックスへの吸着のみによる結合
光増感剤5,10,15,20‐テトラキス(3‐ヒドロキシフェニル)‐ポルフィリン(mTHPP)を含有するPLGA系ナノ粒子の調製と特徴付け;粒子マトリックスへの封入のみによる結合
光増感剤5,10,15,20‐テトラキス(3‐ヒドロキシフェニル)‐クロリン(mTHPC)を含有するPLGA系ナノ粒子の調製と特徴付け;粒子マトリックスへの封入のみによる結合
光増感剤5,10,15,20‐テトラキス(3‐ヒドロキシフェニル)‐ポルフィリン(mTHPP)を含有するPLGA系ナノ粒子の細胞取り込みおよび細胞粘着
光増感剤5,10,15,20‐テトラキス(3‐ヒドロキシフェニル)‐クロリン(mTHPC)を含有するPLGA系ナノ粒子の細胞取り込みおよび細胞粘着
図5AおよびBは、共焦点レーザー走査顕微鏡法によって調べられた光増感剤5,10,15,20‐テトラキス(3‐ヒドロキシフェニル)‐クロリン(mTHPC)を含有するPLGA系ナノ粒子の細胞取り込み/細胞粘着および細胞内分布を示す。HT29細胞は、ガラススライド上で培養され、ナノ粒子と37℃で4時間インキュベートされた。光増感剤mTHPCの赤色自己蛍光が用いられた。ナノ粒子は、封入されたLumogen Yellow(登録商標)(緑色)を含む。
mTHPC光増感剤を含有するPLGAナノ粒子の細胞取り込みおよび光力学活性
表1に挙げた試料がmTHPC‐PLGA‐ナノ粒子の細胞取り込みおよび光毒性に関して調べられた。
本願は、2009年12月11日にKlaus Langerらによって出願された「光力学的療法のための乳酸・グリコール酸共重合体(PLGA)をベースにしたナノ粒子キャリアシステム」というタイトルの米国仮出願番号第61/285,895号の利益と優先権とを主張し、本願で参照することにより組み込まれる。
Claims (12)
- 500nm未満の範囲の乳酸・グリコール酸共重合体(PLGA)粒子と、
治療上有効量のテトラピロール系の疎水性光増感剤と、
ポリ(ビニルアルコール)(PVA)と、
を含み、
抗凍結剤の存在下で凍結乾燥される、
光力学的療法における使用のためのナノ粒子医薬製剤であって、
前記光増感剤は、
式Aのクロリン又はバクテリオクロリン誘導体であって、
R1は、HまたはOHであって、
R2からR5は、‐OH、‐COOH、‐NH2、‐COOX、‐NHX、OX、‐NH‐Y‐COOHまたは‐CO‐Y‐NH2からなる置換基の群から互いに独立して選択され、フェニル環のメタ‐、パラ‐位のいずれかにおける置換基であって、
このとき、
Xは、n=1‐30の(CH2CH2O)nCH3を有するポリエチレングリコール残基あるいは炭水化物基であって、
Yは、n=1‐30のペプチドまたはオリゴペプチドであって、
環Dは、次の構造を有する、
- 前記光増感剤の治療上有効な濃度は、
ナノ粒子mgあたり10から320μgで極めて可変である、
ことを特徴とする請求項1に記載の光力学的療法における使用のためのナノ粒子医薬製剤。 - 前記光増感剤は、
テモポルフィン(mTHPC)、2,3‐ジヒドロキシ‐5,10,15,20‐テトラキス(3‐ヒドロキシフェニル)‐クロリン(mTHPD‐OH)および5,10,15,20‐テトラキス(3‐ヒドロキシフェニル)‐ポルフィリン(mTHPP)からなる群から選択される、
ことを特徴とする請求項1または2に記載の光力学的療法における使用のためのナノ粒子医薬製剤。 - 前記抗凍結剤は、
グルコース、トレハロース、スクロース、ソルビトール、マンニトールおよびこれらの組み合わせからなる群から選択される、
ことを特徴とする請求項1ないし3のいずれか一項に記載の光力学的療法における使用のためのナノ粒子医薬製剤。 - 前記製剤が、標的の細胞および組織への光増感剤の高度な移行のために薬剤標的リガンドのナノ粒子表面への付着を可能とする、
ことを特徴とする請求項1ないし4のいずれか一項に記載の光力学的療法における使用のためのナノ粒子医薬製剤。 - 前記製剤が、静脈注射を含む非経口手段によって投与される、
ことを特徴とする請求項1ないし5のいずれか一項に記載の光力学的療法における使用のためのナノ粒子医薬製剤。 - a.有機溶媒にPLGAを溶解するステップと、
b.ろ過器を通して前記PLGA溶液をろ過し、水溶液を安定化するステップと、
c.粒子表面への吸着結合、封入結合およびこれらの組み合わせによって光増感剤を加えるステップと、
d.PVAを含む安定化水溶液を加え、水中油型ナノエマルションを形成するステップと、
e.得られたナノ粒子を精製するステップと、
を含む、
請求項1ないし6のいずれか一項に記載のナノ粒子医薬製剤の調製方法。 - 前記有機溶媒は、
酢酸エチルである、
ことを特徴とする請求項7に記載の調製方法。 - 光力学的療法における使用のための請求項1ないし6のいずれか一項に記載のナノ粒子医薬製剤。
- 腫瘍およびその他の腫瘍性疾患に対する光力学的療法における使用のための請求項1ないし6のいずれか一項に記載のナノ粒子医薬製剤。
- 皮膚疾患、眼科疾患または泌尿器疾患に対する光力学的療法における使用のための請求項1ないし6のいずれか一項に記載のナノ粒子医薬製剤。
- 関節炎および類似する炎症疾患に対する光力学的療法における使用のための請求項1ないし6のいずれか一項に記載のナノ粒子医薬製剤。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28589509P | 2009-12-11 | 2009-12-11 | |
US61/285,895 | 2009-12-11 | ||
US12/941,447 | 2010-11-08 | ||
US12/941,447 US20110275686A1 (en) | 2009-12-11 | 2010-11-08 | Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt) |
PCT/US2010/059367 WO2011071970A2 (en) | 2009-12-11 | 2010-12-08 | Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt) |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013513610A JP2013513610A (ja) | 2013-04-22 |
JP2013513610A5 JP2013513610A5 (ja) | 2014-08-14 |
JP5868869B2 true JP5868869B2 (ja) | 2016-02-24 |
Family
ID=44146154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012543222A Active JP5868869B2 (ja) | 2009-12-11 | 2010-12-08 | 光力学的療法のための乳酸・グリコール酸共重合体をベースにしたナノ粒子キャリアシステム |
Country Status (7)
Country | Link |
---|---|
US (1) | US20110275686A1 (ja) |
EP (1) | EP2509633A4 (ja) |
JP (1) | JP5868869B2 (ja) |
CN (2) | CN106913533A (ja) |
BR (1) | BR112012013951A2 (ja) |
CA (1) | CA2784005C (ja) |
WO (1) | WO2011071970A2 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9211283B2 (en) * | 2009-12-11 | 2015-12-15 | Biolitec Pharma Marketing Ltd | Nanoparticle carrier systems based on human serum albumin for photodynamic therapy |
GB0922066D0 (en) | 2009-12-17 | 2010-02-03 | Univ Belfast | Modulator |
WO2013012628A2 (en) * | 2011-07-15 | 2013-01-24 | The University Of Georgia Research Foundation, Inc. | Immune-stimulating photoactive hybrid nanoparticles |
JP2013094135A (ja) * | 2011-11-02 | 2013-05-20 | Waseda Univ | 人工ナノ材料の安全性を評価する方法 |
CN103169968B (zh) * | 2013-03-12 | 2014-11-26 | 中国科学院理化技术研究所 | 一种基于白蛋白的疏水二氢卟吩光敏剂纳米药物制剂、制备方法及其应用 |
US10188601B2 (en) * | 2013-09-22 | 2019-01-29 | Brenda Laster | Continuous long-term controlled release of telomerase inhibitors |
CN103933568B (zh) * | 2014-05-12 | 2016-03-30 | 南京师范大学 | 一种水溶性竹红菌素plga纳米粒及其制备方法 |
EP3201201B1 (en) | 2014-09-30 | 2022-01-26 | biolitec unternehmensbeteiligungs II AG | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy |
CN106620893B (zh) | 2015-07-23 | 2021-07-30 | 爱博诺德(北京)医疗科技股份有限公司 | 用于眼部疾病光治疗的材料 |
WO2017019792A1 (en) * | 2015-07-27 | 2017-02-02 | The Texas A&M University System | Surface active nanosystems |
CN105343878B (zh) * | 2015-11-30 | 2018-10-19 | 中国人民解放军第三军医大学第三附属医院 | 还原敏感型水溶性分子靶向光敏剂及其制备方法和应用 |
EP3210626A1 (en) | 2016-02-26 | 2017-08-30 | biolitec Unternehmensbeteiligungs II AG | Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy |
CN109481418B (zh) * | 2017-12-19 | 2022-08-19 | 深圳先进技术研究院 | 抗肿瘤纳米颗粒及其制备方法和应用 |
EP3626268A1 (en) | 2018-09-24 | 2020-03-25 | Westfälische Wilhelms-Universität Münster | Polymer-particle light-cleavable carrier systems for photodynamic therapy |
US20220025185A1 (en) | 2018-12-10 | 2022-01-27 | Universitat Hamburg | Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy |
US20220168421A1 (en) * | 2019-03-08 | 2022-06-02 | North Carolina State University | Photothermal therapy promotes tumor infiltration and antitumor activity of cart t cells |
CN111000804B (zh) * | 2019-12-05 | 2022-02-11 | 东南大学 | 一种甘露糖靶向的热响应铂纳米颗粒及其制备方法和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3372558B2 (ja) * | 1990-09-14 | 2003-02-04 | 中外製薬株式会社 | マイクロカプセル型徐放性製剤及びその製造法 |
AU7127196A (en) | 1995-09-21 | 1997-04-09 | Novartis Ag | Nanoparticles in photodynamic therapy |
JP3765338B2 (ja) * | 1995-12-15 | 2006-04-12 | 武田薬品工業株式会社 | 注射用徐放性製剤の製造法 |
US5829448A (en) * | 1996-10-30 | 1998-11-03 | Photogen, Inc. | Method for improved selectivity in photo-activation of molecular agents |
GB0001455D0 (en) * | 2000-01-21 | 2000-03-15 | Scotia Holdings Plc | Porphyrins and related compounds |
DE60311801T2 (de) * | 2002-05-02 | 2007-11-08 | PR Pharmaceuticals, Inc., Fort Collins | Zusammensetzungen aus östradiol-metaboliten mit kontrollierter freisetzung |
US7455858B2 (en) | 2002-05-16 | 2008-11-25 | Qlt Inc. | Compositions and methods for delivery of photosensitive drugs |
WO2004064751A2 (en) | 2003-01-16 | 2004-08-05 | St. Johns University New York | Nanoparticle based stabilization of ir fluorescent dyes |
US20050048109A1 (en) * | 2003-08-26 | 2005-03-03 | Ceramoptec Industries, Inc. | Non-polar photosensitizer formulations for photodynamic therapy |
WO2006133271A2 (en) * | 2005-06-06 | 2006-12-14 | The General Hospital Corporation | Compositions and methods relating to target-specific photodynamic therapy |
-
2010
- 2010-11-08 US US12/941,447 patent/US20110275686A1/en not_active Abandoned
- 2010-12-08 JP JP2012543222A patent/JP5868869B2/ja active Active
- 2010-12-08 CN CN201710128404.2A patent/CN106913533A/zh active Pending
- 2010-12-08 EP EP10836583.4A patent/EP2509633A4/en active Pending
- 2010-12-08 CA CA2784005A patent/CA2784005C/en not_active Expired - Fee Related
- 2010-12-08 CN CN2010800629259A patent/CN102740892A/zh active Pending
- 2010-12-08 BR BR112012013951A patent/BR112012013951A2/pt not_active IP Right Cessation
- 2010-12-08 WO PCT/US2010/059367 patent/WO2011071970A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20110275686A1 (en) | 2011-11-10 |
BR112012013951A2 (pt) | 2018-06-05 |
EP2509633A4 (en) | 2015-08-26 |
EP2509633A2 (en) | 2012-10-17 |
WO2011071970A2 (en) | 2011-06-16 |
CA2784005A1 (en) | 2011-06-16 |
JP2013513610A (ja) | 2013-04-22 |
CA2784005C (en) | 2018-01-02 |
WO2011071970A3 (en) | 2011-11-17 |
CN106913533A (zh) | 2017-07-04 |
CN102740892A (zh) | 2012-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5868869B2 (ja) | 光力学的療法のための乳酸・グリコール酸共重合体をベースにしたナノ粒子キャリアシステム | |
Escudero et al. | Photodynamic therapy: photosensitizers and nanostructures | |
Sun et al. | One-pot fabrication of hollow porphyrinic MOF nanoparticles with ultrahigh drug loading toward controlled delivery and synergistic cancer therapy | |
Guan et al. | Photodynamic therapy based on nanoscale metal–organic frameworks: from material design to cancer nanotherapeutics | |
Niculescu | Mesoporous silica nanoparticles for bio-applications | |
JP5972171B2 (ja) | 光力学的療法のためのヒト血清アルブミンをベースにしたナノ粒子キャリアシステム | |
Xu et al. | Nanoparticles in sonodynamic therapy: state of the art review | |
Lismont et al. | Metal‐organic framework nanoparticles in photodynamic therapy: current status and perspectives | |
Li et al. | Cancer cell membrane camouflaged cascade bioreactor for cancer targeted starvation and photodynamic therapy | |
Sarcan et al. | Theranostic polymeric nanoparticles for NIR imaging and photodynamic therapy | |
Camerin et al. | The in vivo efficacy of phthalocyanine–nanoparticle conjugates for the photodynamic therapy of amelanotic melanoma | |
Paszko et al. | Nanodrug applications in photodynamic therapy | |
Bayir et al. | Mesoporous silica nanoparticles in recent photodynamic therapy applications | |
KR101035269B1 (ko) | 고분자 유도체-광감작제 복합체를 이용한 새로운 광역학치료제 | |
Chouikrat et al. | Non polymeric nanoparticles for photodynamic therapy applications: recent developments | |
Yang et al. | Metal–organic framework nanoparticles with near-infrared dye for multimodal imaging and guided phototherapy | |
Zhao et al. | DUCNP@ Mn–MOF/FOE as a highly selective and bioavailable drug delivery system for synergistic combination cancer therapy | |
JP2013513610A5 (ja) | ||
CN111956801B (zh) | 光控释放co和阿霉素的纳米药物系统及其制备和应用 | |
Jin et al. | Recent Advances in Bio‐Compatible Oxygen Singlet Generation and Its Tumor Treatment | |
Zhao et al. | Assembled photosensitizers applied for enhanced photodynamic therapy | |
Li | Nanoparticles for photodynamic therapy | |
CN109481696B (zh) | 用于癌症光动力治疗和化学治疗的药物及其制备方法 | |
KR101608122B1 (ko) | 효소 민감성 폴리아미노산과 접합된 광응답제 또는 소광제 및 광역학 치료를 위한 소수성 약물 봉입 나노입자 | |
da Silva et al. | In vitro photodynamic activity of chloro (5, 10, 15, 20-tetraphenylporphyrinato) indium (III) loaded-poly (lactide-co-glycolide) nanoparticles in LNCaP prostate tumour cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140626 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140814 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140819 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141118 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141126 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150421 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150721 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150819 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150918 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151020 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151222 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160106 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5868869 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |